Back to results

Pediatric Open-Label Extension Study

Primary Purpose

Schizophrenia, Autism, Bipolar Depression

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Lurasidone 20, 40, 60, 80 mg, flexibly dosed

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Autism, Lurasidone, Latuda

Eligibility Criteria

6 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
Subject has completed Study D1050301 (Visit 9) OR
Subject has completed Study D1050325 (Visit 9) OR
Subject has completed Study D1050326 (Visit 8)
Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.
A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study
Females who participate in this study:
- are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
- practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
- are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

Exclusion Criteria:

Subject is considered by the investigator to be at imminent risk of suicide.
Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.

Sites / Locations

Harmonex Neuroscience Research
Diligent Clinical Trials, Inc
University of California San Francisco Medical Center
Neuropsychiatric Research Center of Orange County
Sarkis Clinical Trials - Parent
Clinical Neuroscience Solutions, Inc.
APG Research, LLC
University of South Florida
Medical Research Group of Central Florida
University of South Florida Rothman Center of Neuropychiatry
Atlanta Center for Medical Research
Attalla Consultants, LLC
Psychiatric Associates
University Of Kentucky
Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
Kennedy Krieger Institute
Neurobehavioral medicine Group, LLC
St. Charles Psychiatric Associates
Jersey Shore University Medical Center
North Shore/Long Island Jewish PRIME
Dr. Jeanette Cueva
Montefiore Medical Center PRIME
Finger Lakes Clinical Research
Richmond Behavioral Associates
University of Cincinnati Medical Center
University Hospitals Case Medical Center
The Ohio State University Nisonger Center
Cutting Edge Research Group
Pillar Clinical Research, LLC
Family Psychiatry of The Woodlands, P.A.
Ericksen Research & Development, LLC
University of Virginia
Neuroscience, Inc.
Clinical Research Partners, LLC
Carilion Clinic
MHC - Ruse, EOOD
UMHAT "Alexandrovska" EAD
MHAT-Targovishte, AD
DCC "Mladost M" - Varna, OOD
Centro de Investigaciones y Proyectos en Neurociencias CIPNA
E.S.E. Hospital Mental de Antioquia
Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
CHU Nantes - Hôpital Mère-Enfant
Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
Bekes Megyei Pandy Kalman Korhaz
Seoul National University Hospital
Chonnam National University Hospital
Inha University Hospital
Chonbuk National University Hospital
University Malaya Medical Centre
Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
Dr. Jessica Rosas Escobar
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
Accelerium S. de R.L. de C.V.
Instituto de Informacion de Investigacion en Salud Mental
Av Modesto Arreola #917 Ote. Col Centro
Alexian Brothers Health and Wellness Center
West Visayas State University Medical Center
National Center for Mental Health
Veterans Memorial Medical Center
NZOZ Poradnia Zdrowia Psychicznego
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy
Centro de Investigacion Clinica Psiquiatrica
Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
Spitalul Clinic de Psihiatrie Socola
Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara
Sverdiovsk Regional Clinical Psychiatric Hospital
GUZ Lipetsk Regional psychoneurological Hospital #1
Closed corporation "Scientific Center of Personalized Psychiatry"
Scientific Center of Personalized Psychiatry
State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"
SHI "City Psychoneurological dispensary #7 (with Hospital)"
Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin
Bekhterev Institute
Regional Clinical Mental Hospital of Saint Sofiya
FSBSI "Scientific Research Institute of Mental Health"
State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital"
Hospital Marítimo de Torremolinos
RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
SI Institute of Neurology, Psychiatry and Narcology of NAMSU
SI Institute of Children and Adolescents Healthcare of NAMSU
TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
CI Lviv Regional Clinical Psychiatric Hospital
Odesa Regional Psychoneurological Dispensary, Outpatient Dept.
O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
CI Kherson Regional Psychiatric Hospital of Kherson RC
Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Arm Description

Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily

Outcomes

Primary Outcome Measures

Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)

The Safety population consists of all subjects who received at least one dose of study drug in this study.

Secondary Outcome Measures

Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.

Change From Baseline in PANSS Positive Subscale Score

Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity

Change From Baseline in PANSS Negative Subscale Score

Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

Change From Baseline in PANSS General Psychopathology Subscale Score

Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

Change From Baseline in PANSS Excitability Subscale Score

Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.

Change From Baseline in the Clinical Global Impression -Severity Score

Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score

Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score

Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score

Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score

Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity

Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score

Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score

Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Change From Baseline in Clinical Global Impression (CGI) - Severity Score

Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)

Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness

Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score

Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5. Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain

Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score

Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness

Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score

Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score

Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score

Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score

Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score

Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity

Full Information

NCT ID

NCT01914393

First Posted

July 30, 2013

Last Updated

December 18, 2019

Sponsor

Sumitomo Pharma America, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT01914393

Brief Title

Pediatric Open-Label Extension Study

Official Title

A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects

Study Type

Interventional

2. Study Status

Record Verification Date

December 2019

Overall Recruitment Status

Completed

Study Start Date

September 30, 2013 (Actual)

Primary Completion Date

October 17, 2018 (Actual)

Study Completion Date

October 17, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sumitomo Pharma America, Inc.

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Schizophrenia, Autism, Bipolar Depression

Keywords

Schizophrenia, Autism, Lurasidone, Latuda

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Masking Description

Open Label

Allocation

N/A

Enrollment

702 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Arm Type

Experimental

Arm Description

Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily

Intervention Type

Drug

Intervention Name(s)

Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Other Intervention Name(s)

Latuda

Intervention Description

Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed

Primary Outcome Measure Information:

Title

Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)

Description

The Safety population consists of all subjects who received at least one dose of study drug in this study.

Time Frame

During 104 Weeks (2-years) treatment period

Secondary Outcome Measure Information:

Title

Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

Description

Time Frame